Αναζήτηση Δραστικών

CEFTRIAXONE

Εμπορικές Ονομασίες

  • TRAVILAN
    Μορφές: DR.PD.INJ
    Μορφές: PD.SOL.INF
  • ROLISPORIN
    Μορφές: PS.INJ.SOL
    Μορφές: PD.SOL.INF
  • VERACOL
    Μορφές: PS.INJ.SOL
    Μορφές: PD.SOL.INF
  • ANTIBACIN
    Μορφές: PS.INJ.SOL
    Μορφές: PD.SOL.INF
  • RIAXON
    Μορφές: PD.SOL.INF
  • MEDAXONE
    Μορφές: PS.INJ.SOL
    Μορφές: PD.SOL.INF
  • AZATYL
    Μορφές: DR.PD.INJ
    Μορφές: PD.SOL.INF
  • BRESEC
    Μορφές: PS.INJ.SOL
    Μορφές: PD.SOL.INF
  • DRUGBANK - Ceftriaxone
  • indication:

    For the treatment of the infections (respiratory, skin, soft tissue, UTI, ENT) caused by S. pneumoniae, H. influenzae, staphylococci, S. pyogenes (group A beta-hemolytic streptococci), E. coli, P. mirabilis, Klebsiella sp, coagulase-negative staph

  • pharmacology:

  • mechanism:

    Ceftriaxone works by inhibiting the mucopeptide synthesis in the bacterial cell wall. The beta-lactam moiety of Ceftriaxone binds to carboxypeptidases, endopeptidases, and transpeptidases in the bacterial cytoplasmic membrane. These enzymes are involved in cell-wall synthesis and cell division. By binding to these enzymes, Ceftriaxone results in the formation of of defective cell walls and cell death.

  • toxicity:

  • absorprion:

  • halflife:

    5.8-8.7 hours

  • roouteelimination:

    Thirty-three percent to 67% of a ceftriaxone dose was excreted in the urine as unchanged drug and the remainder was secreted in the bile and ultimately found in the feces as microbiologically inactive compounds.

  • volumedistribution:

    * 5.78 to 13.5 L

  • clearance:

    * 0.58 - 1.45 L/h [healthy adults receiving 0.15-3 g of CEFTRIAXONE]